Muhdillyas的个人主页 - 老虎社区

Muhdillyas

Muhdillyas

暂无个人介绍

IP属地：未知

16关注

2粉丝

0主题

0勋章

2021-10-27

$MM2 ASIA LTD.(1B0.SI)$ [微笑]

2021-10-22

$METAL COMPONENT ENGG LTD(5DX.SI)$[龇牙] [龇牙]

2021-10-04

Like

抱歉，原内容已删除

2021-10-02

$Apple(AAPL)$[强] [强]

2021-10-02

$Tesla Motors(TSLA)$[开心] [开心]

2021-09-29

$HATTEN LAND LIMITED(PH0.SI)$[开心] [开心]

2021-09-28

Ok noted

抱歉，原内容已删除

2021-09-28

Ok

Got $1,000? 5 Perfect Stocks to Buy for the Fourth Quarter

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4095586592571660","uuid":"4095586592571660","gmtCreate":1632483527581,"gmtModify":1634818687951,"name":"Muhdillyas","pinyin":"muhdillyas","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":16,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.11","exceedPercentage":"60.39%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":855065835,"gmtCreate":1635316326237,"gmtModify":1635316326237,"author":{"id":"4095586592571660","authorId":"4095586592571660","name":"Muhdillyas","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095586592571660","authorIdStr":"4095586592571660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/1B0.SI\">$MM2 ASIA LTD.(1B0.SI)$</a>&nbsp;[微笑]&nbsp;","listText":"<a href=\"https://laohu8.com/S/1B0.SI\">$MM2 ASIA LTD.(1B0.SI)$</a>&nbsp;[微笑]&nbsp;","text":"$MM2 ASIA LTD.(1B0.SI)$ [微笑]","images":[{"img":"https://static.tigerbbs.com/90f9ac53b67cfbc27b404b376876f8c9","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/855065835","isVote":1,"tweetType":1,"viewCount":817,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":851189177,"gmtCreate":1634880719366,"gmtModify":1634880719366,"author":{"id":"4095586592571660","authorId":"4095586592571660","name":"Muhdillyas","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095586592571660","authorIdStr":"4095586592571660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/5DX.SI\">$METAL COMPONENT ENGG LTD(5DX.SI)$</a>[龇牙]&nbsp;[龇牙]&nbsp;","listText":"<a href=\"https://laohu8.com/S/5DX.SI\">$METAL COMPONENT ENGG LTD(5DX.SI)$</a>[龇牙]&nbsp;[龇牙]&nbsp;","text":"$METAL COMPONENT ENGG LTD(5DX.SI)$[龇牙] [龇牙]","images":[{"img":"https://static.tigerbbs.com/81caf46dcd580c792cbb08eb3ab93af3","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/851189177","isVote":1,"tweetType":1,"viewCount":1108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":820020725,"gmtCreate":1633327794570,"gmtModify":1633327794570,"author":{"id":"4095586592571660","authorId":"4095586592571660","name":"Muhdillyas","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095586592571660","authorIdStr":"4095586592571660"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/820020725","repostId":"2172202963","repostType":4,"isVote":1,"tweetType":1,"viewCount":515,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864264820,"gmtCreate":1633108992325,"gmtModify":1633108992325,"author":{"id":"4095586592571660","authorId":"4095586592571660","name":"Muhdillyas","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095586592571660","authorIdStr":"4095586592571660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>[强]&nbsp;[强]&nbsp;","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>[强]&nbsp;[强]&nbsp;","text":"$Apple(AAPL)$[强] [强]","images":[{"img":"https://static.tigerbbs.com/cb90f4dc5ed2163c669ccdafcbec7a7f","width":"1440","height":"4009"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/864264820","isVote":1,"tweetType":1,"viewCount":954,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":864269893,"gmtCreate":1633107547005,"gmtModify":1633107547005,"author":{"id":"4095586592571660","authorId":"4095586592571660","name":"Muhdillyas","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095586592571660","authorIdStr":"4095586592571660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[开心]&nbsp;[开心]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[开心]&nbsp;[开心]&nbsp;","text":"$Tesla Motors(TSLA)$[开心] [开心]","images":[{"img":"https://static.tigerbbs.com/09db0f3fa157671b1e33d6947336f421","width":"1440","height":"4009"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/864269893","isVote":1,"tweetType":1,"viewCount":590,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":862541869,"gmtCreate":1632895121461,"gmtModify":1632897031454,"author":{"id":"4095586592571660","authorId":"4095586592571660","name":"Muhdillyas","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095586592571660","authorIdStr":"4095586592571660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PH0.SI\">$HATTEN LAND LIMITED(PH0.SI)$</a>[开心]&nbsp;[开心]&nbsp;","listText":"<a href=\"https://laohu8.com/S/PH0.SI\">$HATTEN LAND LIMITED(PH0.SI)$</a>[开心]&nbsp;[开心]&nbsp;","text":"$HATTEN LAND LIMITED(PH0.SI)$[开心] [开心]","images":[{"img":"https://static.tigerbbs.com/8ea0a2cd882da1dc437955469cfc3c0e","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/862541869","isVote":1,"tweetType":1,"viewCount":1172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":862368771,"gmtCreate":1632838226996,"gmtModify":1632839466608,"author":{"id":"4095586592571660","authorId":"4095586592571660","name":"Muhdillyas","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095586592571660","authorIdStr":"4095586592571660"},"themes":[],"htmlText":"Ok noted","listText":"Ok noted","text":"Ok noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862368771","repostId":"2170672462","repostType":4,"isVote":1,"tweetType":1,"viewCount":924,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862368889,"gmtCreate":1632838193463,"gmtModify":1632839466612,"author":{"id":"4095586592571660","authorId":"4095586592571660","name":"Muhdillyas","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095586592571660","authorIdStr":"4095586592571660"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862368889","repostId":"2170672462","repostType":4,"repost":{"id":"2170672462","kind":"highlight","pubTimestamp":1632835246,"share":"https://www.laohu8.com/m/news/2170672462?lang=&edition=full","pubTime":"2021-09-28 21:20","market":"us","language":"en","title":"Got $1,000? 5 Perfect Stocks to Buy for the Fourth Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2170672462","media":"Motley Fool","summary":"Bargains can still be found, even with the broader market near an all-time high.","content":"<p>If investors thought the coronavirus crash was historic, the bounce-back rally from the March 2020 bottom has been even more impressive. The benchmark <b>S&amp;P 500</b> took less than 17 months to double from its lows, and it's now gone 10 months without so much as a 5% downside correction. Patience is truly paying off for long-term investors.</p>\n<p>But just because the broader market is a stone's throw from a record high doesn't mean investors can't still find bargains. If you've got $1,000 ready to invest, which won't be needed for bill or emergencies, the following five stocks would make for perfect buys for the fourth quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8cf8fd6cbc9120f885acecdfb00d5835\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Novavax</h2>\n<p>While I'm generally not a fan of chasing the coronavirus stocks after they've catapulted into the stratosphere, clinical-stage biotech stock <b>Novavax</b> (NASDAQ:NVAX) is the rare exception. It's unlikely to remain a clinical-stage company for much longer and could offer clear advantages that'll help it become a top vaccine player.</p>\n<p>The company's coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373, led to an 89.7% vaccine efficacy (VE) in a large-scale trial in the U.K. earlier this year, and it produced a nearly identical 90.4% VE in a large-scale trial in the U.S. and Mexico in June. This initial efficacy, coupled with the less-than-stellar uptake from <b>AstraZeneca</b>'s and <b>Johnson &amp; Johnson</b>'s COVID-19 vaccines, should open the door for Novavax to become the No. 3 player in developed markets.</p>\n<p>Also working in Novavax's favor is the mutability of the SARS-CoV-2 virus that causes COVID-19. Novavax's drug-development platform is capable of quickly bringing variant-specific vaccines to trial, if necessary. The company could also benefit from the need for booster shots, depending on how long vaccine-based immunity lasts.</p>\n<p>Novavax has an opportunity to beat its peers to market with a combination COVID-19/influenza vaccine, as well. This could be a differentiating vaccine that really allows the company to stand out.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d9e4dd60375f8f383f0c222a7633a4\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Exelixis</h2>\n<p>Biotech stocks are a common theme on this list of perfect stocks to buy for the fourth quarter. Cancer drug developer <b>Exelixis</b> (NASDAQ:EXEL) offers the right blend of growth and value to make patient investors richer.</p>\n<p>The superstar for Exelixis continues to be cancer drug Cabometyx, which derives the bulk of its sales from its first-and-second-line approvals in renal cell carcinoma (RCC) and its approval to treat advanced hepatocellular carcinoma. These indications should help Cabometyx top $1 billion in recurring sales either this year or 2022.</p>\n<p>The only reason this company is as inexpensive as it is now -- 21 times forward-year earnings for sustainable mid-teens sales growth -- is the disappointing update from the Cosmic-312 trial. Though the combination of Cabometyx and atezolizumab led to a statistically significant improvement in progression-free survival for previously untreated liver cancer patients, Exelixis notes that it's unlikely to demonstrate a statistically significant improvement in overall survival by trial completion in early 2022.</p>\n<p>While this might sound like a disappointment, it isn't. It's par for the course when developing blockbuster cancer drugs. Cabometyx failed in a late-stage study targeted at prostate cancer patients in 2014 but has since bounced back to gain numerous approvals. With this key drug being examined in close to six dozen clinical trials, label expansion opportunities remain abundant for Exelixis.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e5596b9cd58d43ee65824bd7892b9c5e\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Broadcom</h2>\n<p>Stepping outside the healthcare arena for the moment, semiconductor solutions provider <b>Broadcom</b> (NASDAQ:AVGO) is a perfect stock to put $1,000 to work in for the fourth quarter. I say \"perfect,\" because Broadcom is at the center of two very sustainable growth trends.</p>\n<p>First, it's going to be a multiyear beneficiary of the rollout of 5G wireless infrastructure. A majority of Broadcom's revenue comes from wireless chips and other accessories found in smartphones. Because it's been a decade since consumers and businesses have benefited from an upgrade to wireless download speeds, the expectation is that we'll see a sustainable, multiyear device replacement cycle. This should allow Broadcom to lock in its orders months or years in advance.</p>\n<p>But it's not just smartphones that should have investors excited about Broadcom. The pandemic has also accelerated the shift of enterprise and consumer data into the cloud. This means data center demand should be strong for a long time to come. Broadcom is a provider of connectivity and access chips used by enterprise data centers.</p>\n<p>The icing on the cake here is that the company has grown its quarterly dividend by more than 5,000% in less than 11 years. Investors can collect a nearly 3% yield as they sit back and watch Broadcom's profitability climb.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2fc0013108c05865a77a8fa2e9b54b23\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Vertex Pharmaceuticals</h2>\n<p>Similar to Exelixis, specialty biotech stock <b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) offers the right blend of double-digit sales growth and insane value (a forward-year price-to-earnings ratio of only 14), which makes it a no-brainer buy for the fourth quarter.</p>\n<p>What allows Vertex to stand out is its overwhelming success in developing multiple generations of treatments for patients with cystic fibrosis (CF). CF is a genetic disease characterized by thick mucus production that can obstruct the pancreas and/or lungs. Vertex's latest treatment, combination therapy Trikafta, was approved five months ahead of the U.S. Food and Drug Administration's review date, and is pacing $5 billion in annual run-rate sales despite hitting pharmacy shelves less than two years ago.</p>\n<p>Keeping with the similarities to Exelixis, Vertex was hit hard twice over the past year after two separate experimental treatments targeting alpha-1 antitrypsin deficiency were discontinued in mid-stage trials. Nevertheless, Vertex has more than a half-dozen combined internal and out-licensed treatments in development for a variety of indications. Even though its CF franchise is well-protected from competition, the company is working on an expansive pipeline of products.</p>\n<p>And don't overlook Vertex's cash pile. It ended June with about $6.7 billion in cash and cash equivalents, which is more than enough to fuel internal development, fund novel partnerships, or make acquisitions.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/39a1727edeb0317fbc6386d8981fd8e0\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Teladoc Health</h2>\n<p>Lastly, buying shares of telemedicine kingpin <b>Teladoc Health</b> (NYSE:TDOC) would be a perfect use of $1,000 for the fourth quarter.</p>\n<p>When the pandemic hit, there's no sugarcoating that Teladoc was in the right place at the right time. With doctors wanting to keep potentially sick and high-risk people out of their offices, they regularly turned to virtual visit platforms, such as those offered by Teladoc. Last year, Teladoc handled almost 10.6 million visits, which was well over double the 4.14 million visits in 2019.</p>\n<p>Some skeptics have cautioned that Teladoc could be a one-hit wonder considering the worst of the pandemic may now be in the rearview mirror. However, this view overlooks the many lasting changes telemedicine brings to the table. It's far more convenient for patients, can allow doctors to keep better tabs on their chronic-care patients, and should result in better patient outcomes and lower total treatment costs for insurers. There's a reason Teladoc's annual sales growth averaged 74% in the six years leading up to the pandemic.</p>\n<p>Teladoc Health also acquired the nation's leading applied health signals company, Livongo Health, in the fourth quarter of 2020. Livongo leans on artificial intelligence to send tips to its chronic-care members to help them lead healthier lives. While most of Livongo' 715,000 chronic-care enrollees are diabetics, it aims to offer its services to those with weight management issues and hypertension, as well. In other words, we're watching the very early innings of a personalized care disruptor.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? 5 Perfect Stocks to Buy for the Fourth Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? 5 Perfect Stocks to Buy for the Fourth Quarter\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 21:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/got-1000-5-perfect-stocks-buy-for-fourth-quarter/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If investors thought the coronavirus crash was historic, the bounce-back rally from the March 2020 bottom has been even more impressive. The benchmark S&P 500 took less than 17 months to double from ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/got-1000-5-perfect-stocks-buy-for-fourth-quarter/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","NVAX":"诺瓦瓦克斯医药","TDOC":"Teladoc Health Inc.","EXEL":"伊克力西斯","AVGO":"博通"},"source_url":"https://www.fool.com/investing/2021/09/28/got-1000-5-perfect-stocks-buy-for-fourth-quarter/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170672462","content_text":"If investors thought the coronavirus crash was historic, the bounce-back rally from the March 2020 bottom has been even more impressive. The benchmark S&P 500 took less than 17 months to double from its lows, and it's now gone 10 months without so much as a 5% downside correction. Patience is truly paying off for long-term investors.\nBut just because the broader market is a stone's throw from a record high doesn't mean investors can't still find bargains. If you've got $1,000 ready to invest, which won't be needed for bill or emergencies, the following five stocks would make for perfect buys for the fourth quarter.\nImage source: Getty Images.\nNovavax\nWhile I'm generally not a fan of chasing the coronavirus stocks after they've catapulted into the stratosphere, clinical-stage biotech stock Novavax (NASDAQ:NVAX) is the rare exception. It's unlikely to remain a clinical-stage company for much longer and could offer clear advantages that'll help it become a top vaccine player.\nThe company's coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373, led to an 89.7% vaccine efficacy (VE) in a large-scale trial in the U.K. earlier this year, and it produced a nearly identical 90.4% VE in a large-scale trial in the U.S. and Mexico in June. This initial efficacy, coupled with the less-than-stellar uptake from AstraZeneca's and Johnson & Johnson's COVID-19 vaccines, should open the door for Novavax to become the No. 3 player in developed markets.\nAlso working in Novavax's favor is the mutability of the SARS-CoV-2 virus that causes COVID-19. Novavax's drug-development platform is capable of quickly bringing variant-specific vaccines to trial, if necessary. The company could also benefit from the need for booster shots, depending on how long vaccine-based immunity lasts.\nNovavax has an opportunity to beat its peers to market with a combination COVID-19/influenza vaccine, as well. This could be a differentiating vaccine that really allows the company to stand out.\nImage source: Getty Images.\nExelixis\nBiotech stocks are a common theme on this list of perfect stocks to buy for the fourth quarter. Cancer drug developer Exelixis (NASDAQ:EXEL) offers the right blend of growth and value to make patient investors richer.\nThe superstar for Exelixis continues to be cancer drug Cabometyx, which derives the bulk of its sales from its first-and-second-line approvals in renal cell carcinoma (RCC) and its approval to treat advanced hepatocellular carcinoma. These indications should help Cabometyx top $1 billion in recurring sales either this year or 2022.\nThe only reason this company is as inexpensive as it is now -- 21 times forward-year earnings for sustainable mid-teens sales growth -- is the disappointing update from the Cosmic-312 trial. Though the combination of Cabometyx and atezolizumab led to a statistically significant improvement in progression-free survival for previously untreated liver cancer patients, Exelixis notes that it's unlikely to demonstrate a statistically significant improvement in overall survival by trial completion in early 2022.\nWhile this might sound like a disappointment, it isn't. It's par for the course when developing blockbuster cancer drugs. Cabometyx failed in a late-stage study targeted at prostate cancer patients in 2014 but has since bounced back to gain numerous approvals. With this key drug being examined in close to six dozen clinical trials, label expansion opportunities remain abundant for Exelixis.\nImage source: Getty Images.\nBroadcom\nStepping outside the healthcare arena for the moment, semiconductor solutions provider Broadcom (NASDAQ:AVGO) is a perfect stock to put $1,000 to work in for the fourth quarter. I say \"perfect,\" because Broadcom is at the center of two very sustainable growth trends.\nFirst, it's going to be a multiyear beneficiary of the rollout of 5G wireless infrastructure. A majority of Broadcom's revenue comes from wireless chips and other accessories found in smartphones. Because it's been a decade since consumers and businesses have benefited from an upgrade to wireless download speeds, the expectation is that we'll see a sustainable, multiyear device replacement cycle. This should allow Broadcom to lock in its orders months or years in advance.\nBut it's not just smartphones that should have investors excited about Broadcom. The pandemic has also accelerated the shift of enterprise and consumer data into the cloud. This means data center demand should be strong for a long time to come. Broadcom is a provider of connectivity and access chips used by enterprise data centers.\nThe icing on the cake here is that the company has grown its quarterly dividend by more than 5,000% in less than 11 years. Investors can collect a nearly 3% yield as they sit back and watch Broadcom's profitability climb.\nImage source: Getty Images.\nVertex Pharmaceuticals\nSimilar to Exelixis, specialty biotech stock Vertex Pharmaceuticals (NASDAQ:VRTX) offers the right blend of double-digit sales growth and insane value (a forward-year price-to-earnings ratio of only 14), which makes it a no-brainer buy for the fourth quarter.\nWhat allows Vertex to stand out is its overwhelming success in developing multiple generations of treatments for patients with cystic fibrosis (CF). CF is a genetic disease characterized by thick mucus production that can obstruct the pancreas and/or lungs. Vertex's latest treatment, combination therapy Trikafta, was approved five months ahead of the U.S. Food and Drug Administration's review date, and is pacing $5 billion in annual run-rate sales despite hitting pharmacy shelves less than two years ago.\nKeeping with the similarities to Exelixis, Vertex was hit hard twice over the past year after two separate experimental treatments targeting alpha-1 antitrypsin deficiency were discontinued in mid-stage trials. Nevertheless, Vertex has more than a half-dozen combined internal and out-licensed treatments in development for a variety of indications. Even though its CF franchise is well-protected from competition, the company is working on an expansive pipeline of products.\nAnd don't overlook Vertex's cash pile. It ended June with about $6.7 billion in cash and cash equivalents, which is more than enough to fuel internal development, fund novel partnerships, or make acquisitions.\nImage source: Getty Images.\nTeladoc Health\nLastly, buying shares of telemedicine kingpin Teladoc Health (NYSE:TDOC) would be a perfect use of $1,000 for the fourth quarter.\nWhen the pandemic hit, there's no sugarcoating that Teladoc was in the right place at the right time. With doctors wanting to keep potentially sick and high-risk people out of their offices, they regularly turned to virtual visit platforms, such as those offered by Teladoc. Last year, Teladoc handled almost 10.6 million visits, which was well over double the 4.14 million visits in 2019.\nSome skeptics have cautioned that Teladoc could be a one-hit wonder considering the worst of the pandemic may now be in the rearview mirror. However, this view overlooks the many lasting changes telemedicine brings to the table. It's far more convenient for patients, can allow doctors to keep better tabs on their chronic-care patients, and should result in better patient outcomes and lower total treatment costs for insurers. There's a reason Teladoc's annual sales growth averaged 74% in the six years leading up to the pandemic.\nTeladoc Health also acquired the nation's leading applied health signals company, Livongo Health, in the fourth quarter of 2020. Livongo leans on artificial intelligence to send tips to its chronic-care members to help them lead healthier lives. While most of Livongo' 715,000 chronic-care enrollees are diabetics, it aims to offer its services to those with weight management issues and hypertension, as well. In other words, we're watching the very early innings of a personalized care disruptor.","news_type":1},"isVote":1,"tweetType":1,"viewCount":622,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":851189177,"gmtCreate":1634880719366,"gmtModify":1634880719366,"author":{"id":"4095586592571660","authorId":"4095586592571660","name":"Muhdillyas","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095586592571660","authorIdStr":"4095586592571660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/5DX.SI\">$METAL COMPONENT ENGG LTD(5DX.SI)$</a>[龇牙]&nbsp;[龇牙]&nbsp;","listText":"<a href=\"https://laohu8.com/S/5DX.SI\">$METAL COMPONENT ENGG LTD(5DX.SI)$</a>[龇牙]&nbsp;[龇牙]&nbsp;","text":"$METAL COMPONENT ENGG LTD(5DX.SI)$[龇牙] [龇牙]","images":[{"img":"https://static.tigerbbs.com/81caf46dcd580c792cbb08eb3ab93af3","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/851189177","isVote":1,"tweetType":1,"viewCount":1108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":862541869,"gmtCreate":1632895121461,"gmtModify":1632897031454,"author":{"id":"4095586592571660","authorId":"4095586592571660","name":"Muhdillyas","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095586592571660","authorIdStr":"4095586592571660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PH0.SI\">$HATTEN LAND LIMITED(PH0.SI)$</a>[开心]&nbsp;[开心]&nbsp;","listText":"<a href=\"https://laohu8.com/S/PH0.SI\">$HATTEN LAND LIMITED(PH0.SI)$</a>[开心]&nbsp;[开心]&nbsp;","text":"$HATTEN LAND LIMITED(PH0.SI)$[开心] [开心]","images":[{"img":"https://static.tigerbbs.com/8ea0a2cd882da1dc437955469cfc3c0e","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/862541869","isVote":1,"tweetType":1,"viewCount":1172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":820020725,"gmtCreate":1633327794570,"gmtModify":1633327794570,"author":{"id":"4095586592571660","authorId":"4095586592571660","name":"Muhdillyas","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095586592571660","authorIdStr":"4095586592571660"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/820020725","repostId":"2172202963","repostType":4,"repost":{"id":"2172202963","kind":"highlight","pubTimestamp":1633316991,"share":"https://www.laohu8.com/m/news/2172202963?lang=&edition=full","pubTime":"2021-10-04 11:09","market":"us","language":"en","title":"Will Airline Stocks Keep Flying Today？","url":"https://stock-news.laohu8.com/highlight/detail?id=2172202963","media":"Motley Fool","summary":"A Wall Street analyst sees upside from here for the airlines.","content":"<span> <h2>What happened</h2> <p>A prominent analyst just issued an upgrade of <strong>Southwest Airlines</strong> <span>(NYSE:LUV)</span>, and his rationale has the whole sector taking flight. Shares of Southwest, <strong>Delta Air Lines</strong> <span>(NYSE:DAL)</span>, <strong>United Airlines Holdings</strong> <span>(NASDAQ:UAL)</span>, and <strong>JetBlue Airways</strong> <span>(NASDAQ:JBLU)</span> were all up more than 5% on Friday morning on commentary that the post-pandemic aviation recovery is far from over.</p> <h2>So what</h2> <p>It's been a turbulent few years for airline stocks, with shares initially hit hard by the pandemic on fears that the drop in travel demand would lead to a rash of airline bankruptcies. But in the U.S., the industry was able to fly through the storm better than expected, and as the vaccines began to roll out, the airlines were part of the so-called \"reopening rally\" earlier this year.</p> \n <div>\n  <img src=\"https://static.tigerbbs.com/2cf782f2a6aff83cf3950fd1a7cc9cd7\" srcset=\"https://g.foolcdn.com/image/?url=https%3A//g.foolcdn.com/editorial/images/645090/silhouette-of-airplane-flying-over-palm-trees-in-sunset-getty.jpg&amp;w=300&amp;op=resize 300w, https://g.foolcdn.com/image/?url=https%3A//g.foolcdn.com/editorial/images/645090/silhouette-of-airplane-flying-over-palm-trees-in-sunset-getty.jpg&amp;w=1000&amp;op=resize 1000w, https://g.foolcdn.com/image/?url=https%3A//g.foolcdn.com/editorial/images/645090/silhouette-of-airplane-flying-over-palm-trees-in-sunset-getty.jpg&amp;w=2000&amp;op=resize 2000w\"> \n  <p>Image source: Getty Images.</p> \n </div> <p>The stocks have mostly gone sideways for a few months now, caught up in a battle between bulls who see significant pent-up demand and bears who worry about added debt taken on during the crisis alongside issues including the Delta variant and continued sluggish demand for business and international travel.</p> <p>But <strong>JP Morgan</strong>'s Jamie Baker thinks the concerns are overblown. On Friday, Baker upgraded Southwest from neutral to overweight and raised his price target to $70 from $64.</p> <p>Baker's reasoning is resonating with investors in several airlines. The analyst wrote airline stocks have \"room to run,\" citing \"encouraging\" JP Morgan internal travel spending data and the recently announced easing of U.S. border restrictions. This remains a domestic-fueled rally, Baker said, but European travel is beginning to spring to life and there are also signs of improved bookings on the all-important New York-London route.</p>\n <div></div> <h2>Now what</h2> <p>Baker only upgraded Southwest, but it is easy to see why the commentary is moving the entire sector. The bullishness goes far beyond the operations of <a href=\"https://laohu8.com/S/AONE.U\">one</a> airline. Southwest, for example, doesn't even fly to Europe.</p> <p>Of course, many risks remain. There is reason to hope the worst of the Delta variant is behind the U.S., but we don't know what might come next from the pandemic and how these developments might impact the quarters to come. And there are some encouraging signs that historically more lucrative segments of the market like business and international travel might be off of their lows. Still, many corporations won't even require employees to return to the office until 2022. Therefore, it is hard to imagine a quick spike in the travel business any time soon.</p> <p>Valuations are reasonable, but uncertainty remains. I agree with Baker's overall optimistic tone, but investors should be aware that this is unlikely to be a straight shot higher and that risks are still in play. For those willing to buckle up for some turbulence and buy right now, it is best to stick with top-quality operators like Southwest and Delta.</p> \n <div></div> </span>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Airline Stocks Keep Flying Today？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Airline Stocks Keep Flying Today？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-04 11:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/01/why-airline-stocks-are-flying-high-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened A prominent analyst just issued an upgrade of Southwest Airlines (NYSE:LUV), and his rationale has the whole sector taking flight. Shares of Southwest, Delta Air Lines (NYSE:DAL), United...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/01/why-airline-stocks-are-flying-high-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/10/01/why-airline-stocks-are-flying-high-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2172202963","content_text":"What happened A prominent analyst just issued an upgrade of Southwest Airlines (NYSE:LUV), and his rationale has the whole sector taking flight. Shares of Southwest, Delta Air Lines (NYSE:DAL), United Airlines Holdings (NASDAQ:UAL), and JetBlue Airways (NASDAQ:JBLU) were all up more than 5% on Friday morning on commentary that the post-pandemic aviation recovery is far from over. So what It's been a turbulent few years for airline stocks, with shares initially hit hard by the pandemic on fears that the drop in travel demand would lead to a rash of airline bankruptcies. But in the U.S., the industry was able to fly through the storm better than expected, and as the vaccines began to roll out, the airlines were part of the so-called \"reopening rally\" earlier this year.\n\n\nImage source: Getty Images.\n The stocks have mostly gone sideways for a few months now, caught up in a battle between bulls who see significant pent-up demand and bears who worry about added debt taken on during the crisis alongside issues including the Delta variant and continued sluggish demand for business and international travel. But JP Morgan's Jamie Baker thinks the concerns are overblown. On Friday, Baker upgraded Southwest from neutral to overweight and raised his price target to $70 from $64. Baker's reasoning is resonating with investors in several airlines. The analyst wrote airline stocks have \"room to run,\" citing \"encouraging\" JP Morgan internal travel spending data and the recently announced easing of U.S. border restrictions. This remains a domestic-fueled rally, Baker said, but European travel is beginning to spring to life and there are also signs of improved bookings on the all-important New York-London route.\n Now what Baker only upgraded Southwest, but it is easy to see why the commentary is moving the entire sector. The bullishness goes far beyond the operations of one airline. Southwest, for example, doesn't even fly to Europe. Of course, many risks remain. There is reason to hope the worst of the Delta variant is behind the U.S., but we don't know what might come next from the pandemic and how these developments might impact the quarters to come. And there are some encouraging signs that historically more lucrative segments of the market like business and international travel might be off of their lows. Still, many corporations won't even require employees to return to the office until 2022. Therefore, it is hard to imagine a quick spike in the travel business any time soon. Valuations are reasonable, but uncertainty remains. I agree with Baker's overall optimistic tone, but investors should be aware that this is unlikely to be a straight shot higher and that risks are still in play. For those willing to buckle up for some turbulence and buy right now, it is best to stick with top-quality operators like Southwest and Delta.","news_type":1},"isVote":1,"tweetType":1,"viewCount":515,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864269893,"gmtCreate":1633107547005,"gmtModify":1633107547005,"author":{"id":"4095586592571660","authorId":"4095586592571660","name":"Muhdillyas","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095586592571660","authorIdStr":"4095586592571660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[开心]&nbsp;[开心]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[开心]&nbsp;[开心]&nbsp;","text":"$Tesla Motors(TSLA)$[开心] [开心]","images":[{"img":"https://static.tigerbbs.com/09db0f3fa157671b1e33d6947336f421","width":"1440","height":"4009"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/864269893","isVote":1,"tweetType":1,"viewCount":590,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":862368771,"gmtCreate":1632838226996,"gmtModify":1632839466608,"author":{"id":"4095586592571660","authorId":"4095586592571660","name":"Muhdillyas","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095586592571660","authorIdStr":"4095586592571660"},"themes":[],"htmlText":"Ok noted","listText":"Ok noted","text":"Ok noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862368771","repostId":"2170672462","repostType":4,"isVote":1,"tweetType":1,"viewCount":924,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862368889,"gmtCreate":1632838193463,"gmtModify":1632839466612,"author":{"id":"4095586592571660","authorId":"4095586592571660","name":"Muhdillyas","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095586592571660","authorIdStr":"4095586592571660"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862368889","repostId":"2170672462","repostType":4,"isVote":1,"tweetType":1,"viewCount":622,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":855065835,"gmtCreate":1635316326237,"gmtModify":1635316326237,"author":{"id":"4095586592571660","authorId":"4095586592571660","name":"Muhdillyas","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095586592571660","authorIdStr":"4095586592571660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/1B0.SI\">$MM2 ASIA LTD.(1B0.SI)$</a>&nbsp;[微笑]&nbsp;","listText":"<a href=\"https://laohu8.com/S/1B0.SI\">$MM2 ASIA LTD.(1B0.SI)$</a>&nbsp;[微笑]&nbsp;","text":"$MM2 ASIA LTD.(1B0.SI)$ [微笑]","images":[{"img":"https://static.tigerbbs.com/90f9ac53b67cfbc27b404b376876f8c9","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/855065835","isVote":1,"tweetType":1,"viewCount":817,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":864264820,"gmtCreate":1633108992325,"gmtModify":1633108992325,"author":{"id":"4095586592571660","authorId":"4095586592571660","name":"Muhdillyas","avatar":"https://static.tigerbbs.com/6281a0ea3a693d0b5bc6706ac5f31250","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095586592571660","authorIdStr":"4095586592571660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>[强]&nbsp;[强]&nbsp;","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>[强]&nbsp;[强]&nbsp;","text":"$Apple(AAPL)$[强] [强]","images":[{"img":"https://static.tigerbbs.com/cb90f4dc5ed2163c669ccdafcbec7a7f","width":"1440","height":"4009"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/864264820","isVote":1,"tweetType":1,"viewCount":954,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"lives":[]}